NAS:LJPC (USA) Also trade in: Germany

La Jolla Pharmaceutical Co

$ 5.82 0.03 (0.52%)
Volume: 315,289 Avg Vol (1m): 615,126
Market Cap $: 157.69 Mil Enterprise Value $: 21.58 Mil
P/E (TTM): 0.00 P/B: 21.22
Earnings Power Value -64.31
Net Current Asset Value -1.16
Tangible Book 0.27
Projected FCF -22.38
Median P/S Value 207.9
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
98.61% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
LJPC: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 2.05, Med: 204.07, Max: 10000
Current: 10000
2.05
10000
Equity-to-Asset 0.06
Equity-to-Asset ranked lower than
77.33% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
LJPC: 0.06
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.06, Med: 0.87, Max: 0.97
Current: 0.06
0.06
0.97
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -8.63
DISTRESS
GREY
SAFE
Beneish M-Score 18.04
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 13.8%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -1268.33
Operating Margin ranked lower than
90.53% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
LJPC: -1268.33
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -12722.73, Med: -2950.14, Max: -106.39
Current: -1268.33
-12722.73
-106.39
Net Margin % -1324.04
Net Margin ranked lower than
90.40% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
LJPC: -1324.04
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -12692.37, Med: -2974.38, Max: -106.26
Current: -1324.04
-12692.37
-106.26
ROE % -228.47
ROE ranked lower than
82.20% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
LJPC: -228.47
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -344.82, Med: -166.82, Max: -48.46
Current: -228.47
-344.82
-48.46
ROA % -82.91
ROA ranked lower than
84.32% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
LJPC: -82.91
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -294.57, Med: -99.38, Max: -46.6
Current: -82.91
-294.57
-46.6
ROC (Joel Greenblatt) % -737.39
ROC (Joel Greenblatt) ranked lower than
58.01% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
LJPC: -737.39
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -94426.32, Med: -4173.94, Max: -737.39
Current: -737.39
-94426.32
-737.39
3-Year Total Revenue Growth Rate 111.90
3-Year Revenue Growth Rate ranked lower than
100.00% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
LJPC: 79.9
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 79.9
Current: 79.9
0
79.9
3-Year Total EBITDA Growth Rate -65.20
3-Year EBITDA Growth Rate ranked lower than
83.67% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
LJPC: -40.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A
3-Year EPS w/o NRI Growth Rate -43.10
3-Year EPS w/o NRI Growth Rate ranked lower than
87.55% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
LJPC: -43.1
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» LJPC's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:LJPC

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare NAS:OSMT XTAE:RDHL AMEX:CVM XKRX:200670 XAMS:KDS SZSE:002680 NAS:ARDX NAS:ADMA OSTO:IBT B XKRX:203690 AMEX:RFL NAS:CERC NAS:EIGR MIL:MLM ROCO:6586 XPAR:POXEL NAS:STRO AMEX:OCX NAS:AFMD NAS:ALDX
Traded in other countries LJPP.Germany
Address 4550 Towne Centre Court, San Diego, CA, USA, 92121
La Jolla Pharmaceutical Co is an American biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.

Ratios

Current vs industry vs history
PB Ratio 21.22
PB Ratio ranked lower than
61.23% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
LJPC: 21.22
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.31, Med: 5.41, Max: 30.15
Current: 21.22
2.31
30.15
PS Ratio 11.33
PS Ratio ranked lower than
90.77% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
LJPC: 11.33
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 11.09, Med: 404.48, Max: 7718
Current: 11.33
11.09
7718
EV-to-EBIT -0.11
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
LJPC: -0.11
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -13.3, Med: -4.05, Max: 0.1
Current: -0.11
-13.3
0.1
EV-to-EBITDA -0.11
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
LJPC: -0.11
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -13.4, Med: -4.1, Max: 0.1
Current: -0.11
-13.4
0.1
EV-to-Revenue 1.58
EV-to-Revenue ranked lower than
84.44% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
LJPC: 1.58
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -1.5, Med: 328.05, Max: 8701.3
Current: 1.58
-1.5
8701.3
Current Ratio 8.65
Current Ratio ranked higher than
83.43% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
LJPC: 8.65
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.26, Med: 8.14, Max: 33.64
Current: 8.65
0.26
33.64
Quick Ratio 8.54
Quick Ratio ranked higher than
83.61% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
LJPC: 8.54
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.26, Med: 8.14, Max: 33.64
Current: 8.54
0.26
33.64
Days Inventory 240.08
Days Inventory ranked lower than
97.30% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
LJPC: 240.08
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 224.38, Med: 224.38, Max: 240.08
Current: 240.08
224.38
240.08
Days Sales Outstanding 53.48
Days Sales Outstanding ranked higher than
57.63% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
LJPC: 53.48
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 50.13, Med: 50.13, Max: 53.48
Current: 53.48
50.13
53.48
Days Payable 532.36
Days Payable ranked lower than
84.89% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
LJPC: 532.36
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 532.36, Med: 1904.31, Max: 1904.31
Current: 532.36
532.36
1904.31

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -11.70
3-Year Share Buyback Rate ranked higher than
50.64% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
LJPC: -11.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -813.2, Med: 0, Max: 0
Current: -11.7
-813.2
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 21.56
Price-to-Tangible-Book ranked lower than
52.46% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
LJPC: 21.56
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 3.14, Med: 5.88, Max: 23.47
Current: 21.56
3.14
23.47
Price-to-Median-PS-Value 0.03
Price-to-Median-PS-Value ranked higher than
81.71% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
LJPC: 0.03
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.03, Med: 1.02, Max: 16.92
Current: 0.03
0.03
16.92
Earnings Yield (Joel Greenblatt) % -772.21
Earnings Yield (Greenblatt) ranked lower than
84.18% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
LJPC: -772.21
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -16932.7, Med: -24.5, Max: 26566.7
Current: -772.21
-16932.7
26566.7

More Statistics

Revenue (TTM) (Mil) $ 13.64
EPS (TTM) $ -6.85
Beta 1.9
Volatility % 69.23
52-Week Range $ 5.01 - 38.39
Shares Outstanding (Mil) 27.1

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y